TECTONIC THERAPEUTIC, INC. Net Income (Loss) Available to Common Stockholders, Diluted
TECTONIC THERAPEUTIC, INC. (TECX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$22.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$22.29M.
- TECTONIC THERAPEUTIC, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$25.24M.
- TECTONIC THERAPEUTIC, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$19.23M.
- TECTONIC THERAPEUTIC, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$19.04M.
- TECTONIC THERAPEUTIC, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$74.15M.
- TECTONIC THERAPEUTIC, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$57.98M.
- TECTONIC THERAPEUTIC, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$42.82M.
- TECTONIC THERAPEUTIC, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$105.89M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$22.29M 10-Q · filed 2026-08-06 | -$47.53M 10-Q · filed 2026-08-06 | -$66.75M derived: sum of 3 quarters · filed 2026-08-06 | -$85.79M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$25.24M 10-Q · filed 2026-05-07 | -$44.47M derived: sum of 2 quarters · filed 2026-05-07 | -$63.50M derived: sum of 3 quarters · filed 2026-05-07 | -$83.49M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$19.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$38.26M derived: sum of 2 quarters · filed 2026-02-26 | -$58.24M derived: sum of 3 quarters · filed 2026-08-06 | -$74.15M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$19.04M 10-Q · filed 2025-11-06 | -$39.02M derived: sum of 2 quarters · filed 2026-08-06 | -$54.92M 10-Q · filed 2025-11-06 | -$67.30M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$19.98M 10-Q · filed 2026-08-06 | -$35.89M 10-Q · filed 2026-08-06 | -$48.26M derived: sum of 3 quarters · filed 2026-08-06 | -$65.98M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$15.91M 10-Q · filed 2026-05-07 | -$28.28M derived: sum of 2 quarters · filed 2026-05-07 | -$46.00M derived: sum of 3 quarters · filed 2026-05-07 | -$58.67M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$12.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$30.09M derived: sum of 2 quarters · filed 2026-02-26 | -$42.76M derived: sum of 3 quarters · filed 2026-02-26 | -$57.98M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$17.72M 10-Q · filed 2025-11-06 | -$30.39M derived: sum of 2 quarters · filed 2025-11-06 | -$45.61M 10-Q · filed 2025-11-06 | -$53.48M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | -$12.67M 10-Q · filed 2025-08-07 | -$27.89M 10-Q · filed 2025-08-07 | -$35.76M derived: sum of 3 quarters · filed 2025-08-07 | -$45.81M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$15.22M 10-Q · filed 2025-05-08 | -$23.09M derived: sum of 2 quarters · filed 2025-05-08 | -$33.14M derived: sum of 3 quarters · filed 2025-05-08 | -$43.60M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$7.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$17.92M derived: sum of 2 quarters · filed 2025-03-20 | -$28.38M derived: sum of 3 quarters · filed 2025-03-20 | -$42.82M 10-K · filed 2025-03-20 | $12.16M 10-K · filed 2024-03-14 | |||
| 2023-09-30 | -$10.05M 10-Q · filed 2024-11-12 | -$21.58M 10-Q · filed 2023-11-09 | -$20.51M derived: sum of 2 quarters · filed 2024-11-12 | -$34.95M 10-Q · filed 2024-11-12 | $20.94M 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | -$10.46M 10-Q · filed 2024-08-14 | $67.48M 10-Q · filed 2023-08-10 | -$24.90M 10-Q · filed 2024-08-14 | $42.52M 10-Q · filed 2023-08-10 | ||||
| 2022-12-31 | -$25.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$48.00M derived: sum of 2 quarters · filed 2024-03-14 | -$76.06M derived: sum of 3 quarters · filed 2024-03-14 | -$105.89M 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | -$22.97M 10-Q · filed 2023-11-09 | -$51.02M derived: sum of 2 quarters · filed 2023-11-09 | -$80.86M 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | -$28.05M 10-Q · filed 2023-08-10 | -$57.89M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |